Chengdu Lingtai Krypton Biotechnology

Chengdu Lingtai Krypton Biotechnology is a Chinese biopharmaceutical company specializing in the development of next-generation RNA therapeutics and advanced delivery systems. The company focuses on overcoming the primary bottleneck of nucleic acid medicine by developing proprietary lipid nanoparticle (LNP) platforms for extrahepatic delivery, allowing mRNA to target organs such as the lungs, spleen, and muscle. Their research and development efforts are directed toward creating a diverse pipeline of mRNA-based treatments for oncology, infectious diseases, and rare genetic disorders. Founded by experts in nucleic acid chemistry, Lingtai Krypton aims to expand the clinical utility of mRNA technology through precise tissue-specific targeting and optimized molecular design.